Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial

Martine Bagot, MD PhD, Pierluigi Porcu, MD, Basem M. William, MRCP,MD, Maxime Battistella, MD PhD, Maarten Vermeer, MD PhD, Sean Whittaker, MD FRCP, Caroline Ram-Wolff, MD, Michael S Khodadoust, MDPhD, Helene Sicard, PhD, Hatem A Azim, Jr., MD PhD, Youn H. Kim, MD

Blood (2018) 132 (Supplement 1): 684.

https://doi.org/10.1182/blood-2018-99-118021

Published: 2018

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Youn H Kim, MD, Marie-France Demierre, MD, Ellen J Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Tadeusz Robak, MD, PhD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Sean Whittaker, MD, FRCP

Blood (2009) 114 (22): 2683.

https://doi.org/10.1182/blood.V114.22.2683.2683

Published: 2009

Journal Articles

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Sean Whittaker, MD, FRCP, Ellen J Kim, MD, Miles Prince, Marie France Demierre, MD, Cynthia Giver, Sagar Lonial, MD, Richard Piekarz, MD, PhD, Youn H Kim, MD, Jean Nichols, PhD, Darrell Nix, Ph.D., Susan Bates, MD

Blood (2009) 114 (22): 3701.

https://doi.org/10.1182/blood.V114.22.3701.3701

Published: 2009

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath

Blood (2008) 112 (11): 263.

https://doi.org/10.1182/blood.V112.11.263.263

Published: 2008

Journal Articles

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Youn H. Kim, MD, Sunil Reddy, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Adam Lerner, MD, Mariefrance Demierre, MD, Madeleine Duvic, MD, Sean Whittaker, MD, FRCP, Tadeusz Robak, MD, Jurgen C. Becker, MD, William McCulloch, MB, FRCP, Archibald G. Prentice, MB, FRCP, FRCPath, on behalf of All Investigators

Blood (2007) 110 (11): 123.

https://doi.org/10.1182/blood.V110.11.123.123

Published: 2007

NARROW

IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only